In addition, anti-CD200 demonstrated efficacy in a B-cell chronic lymphocytic leukemia [34] that led to the use in a clinical trial (clinicaltrials.gov identifier NCT00648739). This evidence concerns the gene CD200 and B-cell chronic lymphocytic leukemia.